Open-label, proof-of-concept study of brexanolone in the treatment of severe postpartum depression

Human Psychopharmacology

Volumn 32, Issue 2, 2017, Pages

  Kanes, Stephen J ^a   Colquhoun, Helen ^a   Doherty, James ^a   Raines, Shane ^b   Hoffmann, Ethan ^a   Rubinow, David R ^c   Meltzer Brody, Samantha ^c  

^a Sage Therapeutics Inc   (United States)

^b 2b Analytics ^*  (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

brexanolone; GABAA receptor; neuroactive steroid; positive allosteric modulation; postpartum depression; psychiatric disorder

Indexed keywords

3ALPHA HYDROXY 5ALPHA PREGNAN 20 ONE; ANTIDEPRESSANT AGENT; BREXANOLONE; SERTRALINE; THYROTROPIN; UNCLASSIFIED DRUG; BETA CYCLODEXTRIN DERIVATIVE; ELTANOLONE;

ADULT; ANXIETY; ARTICLE; BEHAVIOR CHANGE; CASE REPORT; CLINICAL ASSESSMENT; CLINICAL EVALUATION; DISEASE SEVERITY; DIZZINESS; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; EDINBURGH POSTNATAL DEPRESSION SCALE; FEMALE; FOLLOW UP; HAMILTON DEPRESSION RATING SCALE; HOT FLUSH; HUMAN; INJECTION SITE DISCOMFORT; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; OPEN STUDY; OROPHARYNX PAIN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PUERPERAL DEPRESSION; PUERPERIUM; RASH; REMISSION; SIDE EFFECT; THYROTROPIN BLOOD LEVEL; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; DRUG COMBINATION; INTRAVENOUS DRUG ADMINISTRATION; POSTNATAL DEPRESSION; PROOF OF CONCEPT; TREATMENT OUTCOME;

ADULT; BETA-CYCLODEXTRINS; DEPRESSION, POSTPARTUM; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; PREGNANOLONE; PROOF OF CONCEPT STUDY; TREATMENT OUTCOME;

EID: 85016312834     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.2576     Document Type: Article

References (37)

1. Abramowitz, J. S., Meltzer-Brody, S., Leserman, J., Killenberg, S., Rinaldi, K., Mahaffey, B. L., & Pedersen, C. (2010). Obsessional thoughts and compulsive behaviors in a sample of women with postpartum mood symptoms. Archives of Women's Mental Health, 13, 523–530.
2. Amin, Z., Mason, G. F., Cavus, I., Krystal, J. H., Rothman, D. L., & Epperson, C. N. (2006). The interaction of neuroactive steroids and GABA in the development of neuropsychiatric disorders in women. Pharmacology Biochemistry and Behavior, 84, 635–643.
3. A modulators. Psychoneuroendocrinology, 34, 1121–1132.
4. Austin, M. P. V., Middleton, P., Reilly, N. M., & Highet, N. J. (2013). Detection and management of mood disorders in the maternity setting: The Australian clinical practice guidelines. Women and Birth. Australian College of Midwives, 26, 2–9.
5. Beck, C. T. (1995). The effects of postpartum depression on maternal–infant interaction: A meta-analysis. Nursing Research, 44, 298–304.
6. Belelli, D., Harrison, N. L., Maguire, J., Macdonald, R. L., Walker, M. C., & Cope, D. W. (2009). Extrasynaptic GABAA receptors: Form, pharmacology, and function. The Journal of Neuroscience, 29, 12757–12763.
7. Bernstein, I. H., Rush, A. J., Yonkers, K., Carmody, T. J., Woo, A., Mcconnell, K., & Trivedi, M. H. (2008). Symptom features of postpartum depression: Are they distinct? Depression and Anxiety, 25, 20–26.
8. Bloch, M., Schmidt, P. J., Danaceau, M., Murphy, J., Nieman, L., & Rubinow, D. R. (2000). Effects of gonadal steroids in women with a history of postpartum depression. American Journal of Psychiatry, 157, 924–930.
9. Cox, J. L., Holden, J. M., & Sagovsky, R. (1987). Detection of postnatal depression: Development of the 10-item Edinburgh Postnatal Depression scale. British Journal of Psychiatry, 150, 782–786.
10. De Crescenzo, F., Perelli, F., Armando, A., & Vicari, S. (2014). Selective serotonin reuptake inhibitors (SSRIs) for post-partum depression (PPD): A systematic review of randomized clinical trials. Journal of Affective Disorders, 152-154, 39–44.
11. Earls, M. F. (2010). Incorporating recognition and management of perinatal and postpartum depression into pediatric practice. Pediatrics, 126, 1032–1039.
12. Fihrer, I., Mcmahon, C. A., & Taylor, A. J. (2009). The impact of postnatal and concurrent maternal depression on child behaviour during the early school years. Journal of Affective Disorders, 119, 116–123.
13. Gavin, N. I., Gaynes, B. N., Lohr, K. N., Meltzer-Brody, S., Gartlehner, G., & Swinson, T. (2005). Perinatal depression: A systematic review of prevalence and incidence. Obstetrics and Gynecology, 106, 1071–1083.
14. Hamilton, M. (1960). A rating scale for depression. Journal of Neurology, Neurosurgery, and Psychiatry, 23, 56–62.
15. Hellgren, C., Åkerud, H., Skalkidou, A., Bäckström, T., & Sundström-Poromaa, I. (2014). Low serum allopregnanolone is associated with symptoms of depression in late pregnancy. Neuropsychobiology, 69, 147–153.
16. Hendrick, V., Altshuler, L., Strouse, T., & Grosser, S. (2000). Postpartum and nonpostpartum depression: Differences in presentation and response to pharmacologic treatment. Depression and Anxiety, 11, 66–72.
17. Hoddes, E., Zarcone, V., Smythe, H., Phillips, R., & Dement, W. C. (1973). Quantification of sleepiness: A new approach. Psychophysiology, 10, 431–436.
18. Howard, L. M., Flach, C., Mehay, A., Sharp, D., & Tylee, A. (2011). The prevalence of suicidal ideation identified by the Edinburgh Postnatal Depression Scale in postpartum women in primary care: Findings from the RESPOND trial. BMC Pregnancy and Childbirth, 11, 57.
19. Kim, D. R., Epperson, C. N., Weiss, A. R., & Wisner, K. L. (2014). Pharmacotherapy of postpartum depression: An update. Expert Opinion on Pharmacotherapy, 15, 1223–1234.
20. Kimmel, M. C., Lara-Cinisomo, S., Melvin, K., Di Florio, A., Brandon, A., & Meltzer-Brody, S. (2016). Treatment of severe perinatal mood disorders on a specialized perinatal psychiatry inpatient unit. Archives of Women's Mental Health, 19, 645–653.
21. Kroenke, K., Spitzer, R. L., & Williams, J. B. (2001). The PHQ-9: Validity of a brief depression severity measure. Journal of General Internal Medicine, 16, 606–613.
22. Lambert, J. J., Belelli, D., Harney, S. C., Peters, J. A., & Frenguelli, B. G. (2001). Modulation of native and recombinant GABA(A) receptors by endogenous and synthetic neuroactive steroids. Brain Research. Brain Research Reviews, 37, 68–80.
23. Luisi, S., Petraglia, F., Benedetto, C., Nappi, R. E., Bernardi, F., Fadalti, M., … Genazzani, A. R. (2000). Serum allopregnanolone levels in pregnant women: Changes during pregnancy, at delivery, and in hypertensive patients. Journal of Clinical Endocrinology and Metabolism, 85, 2429–2433.
24. AR plasticity during pregnancy: Relevance to postpartum depression. Neuron, 59, 207–213.
25. Meltzer-Brody, S., Brandon, A. R., Pearson, B., Burns, L., Raines, C., Bullard, E., & Rubinow, D. (2014). Evaluating the clinical effectiveness of a specialized perinatal psychiatry inpatient unit. Archives of Women's Mental Health, 17, 107–113.
26. Misri, S., Swift, E., Abizadeh, J., & Shankar, R. (2016). Overcoming functional impairment in postpartum depressed or anxious women: A pilot trial of desvenlafaxine with flexible dosing. Ther Adv Psychopharmacol, 6, 269–276.
27. Molyneaux, E., Howard, L. M., Mcgeown, H. R., Karia, A. M., & Trevillion, K. (2014). Antidepressant treatment for postnatal depression. Cochrane Database of Systematic Reviews, CD002018.
28. Nappi, R. E., Petraglia, F., Luisi, S., Polatti, F., Farina, C., & Genazzani, A. R. (2001). Serum allopregnanolone in women with postpartum “blues”. Obstetrics and Gynecology, 97, 77–80.
29. O'connor, T. G., Monk, C., & Burke, A. S. (2016). Maternal affective illness in the perinatal period and child development: Findings on developmental timing, mechanisms, and intervention. Current Psychiatry Reports, 18, 24.
30. Paoletti, A. M., Romagnino, S., Contu, R., Orrù, M. M., Marotto, M. F., Zedda, P., … Melis, G. B. (2006). Observational study on the stability of the psychological status during normal pregnancy and increased blood levels of neuroactive steroids with GABA-A receptor agonist activity. Psychoneuroendocrinology, 31, 485–492.
31. Posner, K., Brown, G. K., Stanley, B., Brent, D. A., Yershova, K. V., Oquendo, M. A., … Mann, J. J. (2011). The Columbia-Suicide Severity Rating Scale: Initial validity and internal consistency findings from three multisite studies with adolescents and adults. American Journal of Psychiatry, 168, 1266–1277.
32. Schiller, C. E., Meltzer-Brody, S., & Rubinow, D. R. (2014a). The role of reproductive hormones in postpartum depression (pp. 1–12). September: CNS Spectr.
33. Schiller, C. E., Schmidt, P. J., & Rubinow, D. R. (2014b). Allopregnanolone as a mediator of affective switching in reproductive mood disorders. Psychopharmacology (Berlin), 5, 3557–3567.
34. Schiller, C. E., Meltzer-Brody, S., & Rubinow, D. R. (2015). The role of reproductive hormones in postpartum depression. CNS Spectrums, 20, 48–59.
35. Schule, C., Nothdurfter, C., & Rupprecht, R. (2014). The role of allopregnanolone in depression and anxiety. Progress in Neurobiology, 113, 79–87.
36. Spitzer, R. L., Kroenke, K., Williams, J. B. W., & Löwe, B. (2006). A brief measure for assessing generalized anxiety disorder: The GAD-7. Archives of Internal Medicine (Chicago, Ill.: 1908), 166, 1092–1097.
37. Zimmerman, M., Martinez, J. H., Young, D., Chelminski, I., & Dalrymple, K. (2013). Severity classification on the Hamilton Depression Rating Scale. Journal of Affective Disorders, 150, 384–388.